Senator Sheldon Whitehouse has sold shares of Amgen Inc (AMGN), with the transaction valued between $1,000 and $15,000. This sale occurred on September 3, 2025, and was reported 29 days later, in compliance with the STOCK Act's 30-day reporting requirement.
The transaction highlights the ongoing scrutiny of congressional trading activities, which are designed to promote transparency and prevent insider trading. While this sale was made through Whitehouse's own account, it does not inherently reflect a negative outlook on Amgen.
Amgen Inc, a leading biotechnology company headquartered in Thousand Oaks, California, focuses on the discovery, development, manufacture, and marketing of human therapeutics. The company employs approximately 28,000 individuals and operates within the human therapeutics segment, boasting a diverse portfolio of marketed products including EPOGEN, Aranesp, and Repatha.
As of November 18, 2025, Amgen's market capitalization stands at $184.0 billion, with a P/E ratio of 26.27 and an EPS of 12.94. The company's upcoming earnings are anticipated on April 28, 2026, with an estimated EPS of $5.16 and revenue of $8.8 billion.
Congressional trading disclosures serve as a tool for transparency regarding the financial activities of elected officials. While legal when properly disclosed, such transactions should be viewed as one of many data points rather than definitive indicators of stock performance. Research on congressional trading suggests mixed results regarding its predictive value, with some studies indicating slight outperformance of congressional portfolios, while others find no significant advantage.
Investors interested in these patterns should consider broader trends across multiple representatives and sectors rather than focusing solely on individual transactions.